Xeraya gives All G a Southeast Asian foothold

INTRODUCTION

All G has added Xeraya Capital to its pre-Series B financing. The Malaysian investor could help the fermentation protein producer reach Southeast Asian nutrition markets, where local access may count as much as capital.

Vegconomist reported the addition on 11 August 2026. Xeraya, a life-sciences investment firm based in Kuala Lumpur, joins Savencia, Döhler Ventures, Agronomics and Ellerston Capital in the convertible note round. All G makes bovine and human milk proteins without livestock through precision fermentation. It wants to sell those ingredients into functional nutrition and infant formula. The investment amount, note terms and resulting ownership remain undisclosed, according to Vegconomist.

All G presents Xeraya’s regional contacts as a route to commercial opportunities across Southeast Asia. That claim matters because regulatory clearance alone does not secure customers, distribution or manufacturing partners. Separate evidence shows that Malaysia and India are adding research, advice and student talent around cellular agriculture. The APAC Society for Cellular Agriculture, known as APAC-SCA, has admitted Universiti Sains Malaysia and Altruistic Innovations as strategic members, Vegconomist reported on 12 August 2026. Good Food Institute directories also list new university groups across India, Argentina, Canada, Finland and the United States. These organisations have no disclosed role in All G’s financing. They do show the wider network into which Xeraya is investing.

THE DECISION

Xeraya’s participation adds a Malaysian institution to a financing group that already spans corporate and financial investors. Savencia is a French dairy group. Döhler Ventures, Agronomics and Ellerston Capital were existing backers before Xeraya entered, according to Vegconomist. The source does not identify a final close, target size or conversion trigger for the note. It also gives no valuation. The firm’s entry therefore signals interest rather than establishing the scale of its conviction. Xeraya was founded in 2012 and invests internationally across biotechnology, agricultural technology, medical technology and healthcare, Vegconomist reports. That remit fits All G’s position between food ingredients and health-related nutrition. Yet fit should not be confused with proof of demand. Xeraya CEO Fares Zahir said the firm backs biology tied to better health and intends to support All G’s regional expansion. Neither party named a customer, distributor or production site linked to the investment.

All G chief executive Jan Pacas described Xeraya’s decision as support for the company’s science and purpose, according to Vegconomist. That is management’s interpretation. The harder evidence lies in the investor joining the note and in All G’s prior commercial and regulatory steps. Vegconomist reports that All G began selling its LFX low-iron lactoferrin in the United States in July 2026. The publication also says the company obtained China’s first approval for recombinant lactoferrin in 2024. These developments give Xeraya more to assess than a laboratory programme. The sources do not disclose US sales volumes, prices or buyers. They also do not explain the scope of the Chinese clearance or whether All G has generated revenue there. Regulatory entry and material sales are different achievements, despite their frequent proximity in company announcements.

FINANCING

The new commitment follows an earlier A$10 million raise in December 2025, according to Vegconomist. All G paired that financing with a joint venture involving Armour Protéines, a dairy ingredients business within Savencia. The source does not divide the A$10 million among investors or state how much went to the joint venture. It also gives no spending plan. The pre-Series B instrument adds another layer of uncertainty because convertible notes usually defer some ownership questions until a later event, although the supplied sources do not state this note’s mechanics. No conclusion can be drawn about dilution, maturity or investor rights. The absence of a disclosed cheque also prevents comparison between Xeraya and the round’s other participants. Its practical value may rest in introductions. That remains a company claim until a named commercial agreement appears.

All G says Xeraya can speed access to nutrition opportunities across Southeast Asia, according to Vegconomist. Xeraya says it sees a credible route into the region’s expanding markets. Neither source provides market size, growth figures or country priorities. The references to infant formula demand are similarly unsupported by numbers in the supplied material. Investors may regard regional demand as attractive, but the evidence here establishes only their stated view. The distinction matters for a product such as lactoferrin. All G targets categories where buyers must weigh price, purity, function, supply and regulatory status. Vegconomist describes lactoferrin as a milk protein associated with iron control and immune support. The source supplies no clinical results for All G’s ingredient. Health-related positioning therefore needs separation from demonstrated outcomes for a particular formulation.

PROCESS

Precision fermentation gives microorganisms genetic instructions to make specified proteins. The supplied sources identify this as All G’s production route but provide no organism, vessel scale, yield or downstream recovery data. All G says its platform can produce lactoferrin and other bovine or human milk proteins without animals, according to Vegconomist. Xeraya bases part of its rationale on the platform’s claimed ability to scale. No production cost or capacity figure supports that view in the material provided. The process also differs from cultivated meat, which grows animal cells. That distinction helps explain why adjacent scientific networks can still matter. Both fields need bioprocess skills, controlled media, scale-up knowledge and regulatory expertise, but the sources do not claim that All G uses cultivated-meat methods.

A Good Food Institute event scheduled for 13 August focuses on growth factors as a cost and scale constraint for cultivated meat. The organisation lists Cameron Semper of the University of Calgary as the speaker and sets the virtual session for 1pm to 2.30pm EDT. The event description says researchers are examining ways to cut growth-factor expense. The source provides no results because it describes an upcoming session. Growth factors are not identified as an All G cost in the supplied material. The listing instead shows how technical bottlenecks differ within cellular agriculture. All G seeks scale for a secreted protein made by fermentation. Cultivated-meat developers must also manage inputs that direct animal-cell growth. Capital interested in one field cannot assume that progress transfers neatly to the other.

REGIONAL NETWORK

APAC-SCA’s latest additions provide firmer evidence of institutional activity in Malaysia. Universiti Sains Malaysia joined through Mohamad Hafizi Abu Bakar, a senior lecturer and principal investigator in the School of Industrial Technology’s Bioprocess Technology Division, according to Vegconomist. His work covers industrial biotechnology, cellular agriculture, cultivated meat, bioprocessing and media without serum. APAC-SCA identified sustainable processing, research partnerships and talent development as possible areas of work. The membership does not create a link to All G or Xeraya. It does place relevant expertise within the same national setting as the investor. Malaysia’s role in this story is therefore broader than finance, although the commercial and academic strands remain separate on the available evidence.

Universiti Sains Malaysia ranked fifth among 1,603 institutions in the Times Higher Education Sustainability Impact Ratings 2026, Vegconomist reports. The university had shared 14th place a year earlier. It was the highest Asian institution in the assessment and retained first place for SDG 17, which concerns partnerships, according to the same report. These rankings measure a wider sustainability agenda rather than cellular agriculture output. They do not establish patents, production capacity or commercial readiness. APAC-SCA programme director Peter Yu said the university would contribute bioprocess and cellular-agriculture knowledge. His assessment is plausible given Abu Bakar’s stated research fields, but the sources name no joint project, grant or timetable. Membership creates a forum. Work still requires funding and defined goals.

APAC-SCA also admitted Altruistic Innovations, a food biotechnology consultancy founded by Sruthi Sadanand. Vegconomist says the firm advises companies, investors, universities and start-ups on cultivated meat, products, partnerships and technical or market checks. Its previous work has examined India’s fermentation capacity, processing infrastructure, patent position and regulatory routes. Sadanand has worked in India and Singapore on product development, market development and network building, according to Vegconomist. She views Singapore’s coordination of research, talent, regulators and companies as useful for other countries. India offers science, engineering, biotechnology and scale, in her account. APAC-SCA says it plans to connect Indian participants with counterparts in Southeast Asia, Singapore, Japan, Korea and Australia. These are organisational intentions, not disclosed transactions.

The two additions use APAC-SCA’s strategic membership category. Vegconomist says this class covers universities, public bodies, non-profit groups and similar partners rather than direct makers of cultivated products. Companies working in cultivated meat and seafood formed the association in March 2022, according to the publication. Its membership during 2026 has also included Sumitomo Riko, Food & Bio Cluster Denmark and the Malaysian Bioeconomy Development Corporation. That mix shows a deliberate attempt to connect industry with institutions around it. The approach supports Xeraya’s thesis that relationships can help regional entry. It does not validate All G’s specific sales plan. APAC-SCA discusses cellular agriculture broadly, while All G’s immediate product comes from precision fermentation. The overlap lies in biotechnology infrastructure and policy, not in identical production systems.

TALENT

Good Food Institute directories record another layer of network building. The UMBC Alt Protein Project at the University of Maryland, Baltimore County was founded in 2026, according to the institute. The student group seeks to teach people about alternative proteins and provide tasting opportunities. It also aims to reduce stigma and welcomes vegans, people shifting towards plant-based diets and those who still eat animal products. This focus addresses public reception rather than All G’s route into infant nutrition. Consumer acceptance can shape the wider field, but the listing supplies no survey, membership total or programme outcome. The group is based at the university’s Baltimore campus. Its inclusion in the institute’s directory shows a formal presence, not evidence of technical or commercial output.

Two Canadian entries take a more research-led approach. The McGill Alt Protein Project was founded at McGill University in 2026, the Good Food Institute directory states. It describes itself as a student-run effort covering education, research and community formation. The group wants McGill to become a durable base for talent and open-access work across disciplines. The University of Alberta Alternative Protein Project also dates from 2026, according to the institute. It brings together food science, agriculture, biotechnology, engineering and public policy. The Alberta group says it connects students, researchers and industry partners around food-system work. Neither directory entry reports funding, publications or industrial partners by name. Their value to companies such as All G remains potential rather than measured.

The University of Nebraska-Lincoln entry narrows its attention towards plant proteins and fermentation. The Good Food Institute says its student-led project began in 2026. The group wants to support new ingredients and processing technologies as complementary parts of the food system. That emphasis places fermentation beside plant-derived products rather than treating all alternative proteins as one technical category. The Helsinki Alt Protein Project, also founded in 2026 according to the institute, follows a different model. It seeks to link students, researchers and industry professionals throughout the Helsinki area and beyond. Its stated tools are education, joint work and research participation. The directory offers no project list for either chapter. Both entries nevertheless identify multidisciplinary talent formation as an aim, a recurring need across fermentation and cultivated food.

South America has two listed groups in Argentina. The UNLP Alt Protein Project operates at Universidad Nacional de la Plata and was founded in 2026, according to the Good Food Institute. It seeks a regional ecosystem across the Southern Cone and points to university strengths in biotechnology, food science and chemical technology. The entry also names CIDCA, the Center for Research, as a specialist research institution. The supplied text ends before detailing its work. The UADE Alt Protein Project at Universidad Argentina de la Empresa likewise began in 2026, the institute reports. Its team spans food engineering, biotechnology and strategic communication. Unlike some plant-focused chapters, UADE explicitly includes cultivated meat and precision fermentation alongside plant-based products. No disclosed programme connects either Argentine group with All G.

India’s two Good Food Institute entries complement Altruistic Innovations’ advisory role. The GBU Smart Protein Project at Gujarat Biotechnology University was founded in 2026, according to the directory. It concentrates on plant proteins and proteins made through fermentation. The group promotes open knowledge and wants students to turn basic biology into viable food applications. The Sathyabama Smart Protein Project at the Sathyabama Institute of Science and Technology in Chennai also dates from 2026, the institute states. Faculty mentor Karthick Velu guides its work on awareness, cross-disciplinary research and talent development. The supplied entries give no budgets, facilities or results. India therefore shows signs of organised interest, but the evidence stops short of industrial capacity.

LIMITS

The investment announcement leaves the most useful commercial questions unanswered. Vegconomist gives no sum for Xeraya’s commitment, no date for completing the pre-Series B round and no terms for the convertible note. All G names no Southeast Asian country as its first target. It discloses no regional regulatory filing, infant-formula partner or distribution contract. Xeraya’s connections may help, but the source identifies none. The US launch of LFX and the Chinese clearance provide reference points, yet neither comes with revenue, volume or customer data. Claims about scale also lack fermentation capacity, yield and cost figures. The academic and association sources add evidence of talent and institutional interest. They do not fill those commercial gaps.

The counter-argument is that an investor with local life-sciences experience can create value before contracts become public. Xeraya’s Kuala Lumpur base and its biotechnology remit support that case, according to Vegconomist. APAC-SCA’s Malaysian and Indian expansion also shows that regional networks are becoming more organised. Yet the evidence does not show that these developments share personnel, funding or programmes with All G. Good Food Institute listings across nine universities describe ambitions rather than results. Most were founded in 2026, according to the institute, so long-term output cannot be assessed from the supplied text. The sober reading is narrower. All G has added a relevant investor, but the commercial bridge into Southeast Asia has not yet been built in public.

CONCLUSION

Xeraya gives All G a credible regional contact, not proof of a regional business. The judgement should turn on disclosed customers, approvals and production economics, because capital without those details remains an introduction rather than a market.